For the current week, the overall ratings of four Medical Devices stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Alere (NYSE:ALR) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Alere develops and manufactures patient diagnosis, monitoring, and health management products and services for cardiology, infectious diseases, toxicology, diabetes, oncology, and womens health in the United States and internationally. In Portfolio Grader’s specific subcategories of Earnings Momentum and Equity, ALR also gets F’s. For a full analysis of ALR stock, visit Portfolio Grader.
RTI Biologics‘s (NASDAQ:RTIX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. RTI Biologics processes human and animal musculoskeletal tissues in producing allograft and xenograft implants. The stock also gets an F in Earnings Momentum. The stock currently has a trailing PE Ratio of 28.20. For more information, get Portfolio Grader’s complete analysis of RTIX stock.
The rating of AtriCure (NASDAQ:ATRC) slips from a D to a F. AtriCure engages in developing, manufacturing, and selling cardiac surgical ablation systems designed to create precise lesions or scars in cardiac tissue in the United States and internationally. The stock also rates an F in Equity. For a full analysis of ATRC stock, visit Portfolio Grader.
The rating of Thoratec (NASDAQ:THOR) declines this week from a C to a D. Thoratec is involved in the development, manufacture and marketing of proprietary medical devices used for circulatory support. The stock’s trailing PE Ratio is 26.10. To get an in-depth look at THOR, get Portfolio Grader’s complete analysis of THOR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.